CMPS

#2642
COMPASS Pathways Plc American Depository Shares
5.8501 USD
+1.39%
Сектор: Здравоохранение
Базовая: USD
Валюта прибыли: USD
Дневной диапазон
5.8450
5.8600
Годовой диапазон
4.8800
8.9000
Дневное изменение
+1.39%
Месячное изменение
-9.02%
6-месячное изменение
-8.16%
Годовое изменение
-8.16%
Предыдущее закрытие
5.7700
Открыть
5.8450
Bid
Ask
Минимум
5.8450
High
5.8600
Объем
39
Открыть полный график

Financials

Обзор Отчетность Статистика
Квартал Год
  • Market Capitalization 754.2142 M
  • Employee 156
  • Founded 2016
  • CEO N/A
  • Website compasspathways.com
  • Headquarter United Kingdom
  • FIGI BBG00X0VY2N1
  • Industry Technology
Общий доход
Чистая прибыль
Базовая прибыль на акцию
Общий долг
Свободный денежный поток
Денежные средства и эквиваленты
Коэффициент цена/прибыль
-2.24
Коэффициент цена/денежный поток
185.88

COMPASS Pathways Plc - American Depository Shares

Compass Pathways, or COMPASS Pathways, is a British pharmaceutical company developing psychedelics as potential medicines. Its main drug candidate, psilocybin, is currently in phase 3 clinical trials for treatment-resistant depression. This candidate has received breakthrough therapy status from the U.S. Food and Drug Administration. It is the most advanced psychedelic drug candidate in development besides Lykos Therapeutics's midomafetamine. Compass Pathways is the largest company in the psychedelic medicine industry and, in 2020, was the first psychedelic medicine company to be listed on the NASDAQ. It has faced criticism for patenting psychedelic drugs and even certain psilocybin mushroom species. In October 2024, after the FDA rejected Lykos Therapeutics's MDMA for post-traumatic stress disorder New Drug Application, Compass Pathways said that it would lay off 30% of its workforce and narrow its research focus. Compass Pathways has entered partnerships with several independent psychedelic academic scientists, including Jason Wallach, Hamilton Morris, and Adam Halberstadt among others, to develop novel psychedelic drugs for potential medical use.

Новости